https://www.selleckchem.com/products/jnk-in-8.html
benefit from anti-PD-1/PD-L1 therapy. The use of antibiotics (AT and proton-pump inhibitors (PPI) alters the composition and diversity of the gut microbiota, which can influence the immune system, consequently interfering with response to anti-PD1 immune checkpoint inhibitors (ICI). We assessed the impact of ATB and/or PPI use on the efficacy and safety of ICI. Two hundred twelve patients treated with anti-PD1 ICI for non-small cell lung carcinoma, melanoma, upper airway digestive tract carcinoma or renal cell carcinoma were re
Like
Comment
Share
